Tian Zhang, MD, MHS
Dr. Zhang received her MD from the Harvard-MIT Health Sciences and Technology (HST) program and completed post-graduate training at Duke University, where she remained on faculty until 2021. She is currently Associate Professor and Director of Clinical Research within the Division of Hematology and Oncology and Department of Internal Medicine at University of Texas Southwestern Medical Center, Harold C. Simmons Comprehensive Cancer Center. She leads the multi-disease and precision oncology portfolio of trials within the cancer center. Clinically she specializes in genitourinary malignancies and is a clinical researcher focused on improving novel therapies and biomarkers for patients with renal, prostate, and urothelial cancers. She serves as co-chair of the NCI GU Steering Committee Renal Task Force.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Acerta, Novartis, Merrimack, Abbvie/StemCentrx, Merck, Regeron, Mirati Therapeutics, Janssen, AstraZeneca, Pfizer, OmniSeq, Personal Genome Diagnostics, AstellasTopic:PI (research funding)Date added:03/22/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Pfizer, MJH Associates, Vaniam, Aptitude Health, PeerView, Clinical Care OptionsTopic:ConsultantDate added:03/22/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Merck, Exelixis, Sanofi-Aventis, Janssen, AstraZeneca, Pfizer, Amgen, BMS, Pharmacyclics, SeaGen, Calithera, Dendreon, QED Therapeutics, Eisai, Aveo Pharmaceuticals, Bayer, Eli LillyTopic:Advisory BoardDate added:03/22/2022